An excess of insulin relative to food intake, energy expenditure, or both may lead to severe and sometimes prolonged and life-threatening hypoglycemia and hypokalemia see Warnings and Precautions (5.3, 5.6). Mild episodes of hypoglycemia usually can be treated with oral glucose.L42375 Lowering the insulin dosage, and adjustments in meal patterns, or exercise may be needed. More severe episodes with coma, seizure, or neurologic impairment may be treated with a glucagon product for emergency use or concentrated intravenous glucose.L42375 Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness.L42375Individuals may become unconscious in severe cases of hypoglycemia. Injection site reactions may also occur. Symptoms include: redness, inflammation, bruising, swelling and itching at the injection site.L42375 After apparent clinical recovery from hypoglycemia, continued observation and additional carbohydrate intake may be necessary to avoid recurrence of hypoglycemia. Hypokalemia must be corrected appropriately.L42375
Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.A2358, A2359, A2360, A44 Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.A2358, A2359, A2360, A44 Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.A2358, A2359, A2360, A44 The absorption of glucose into cells allows for its transformation into glycogen or fat for storage.A2358, A2359, A2360, A44 Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.A2358, A2359, A2360, A44
Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels.A2358, A2359, A2360, A44 As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin detemir, to lower glucose levels in the blood.A2358, A2359, A2360, A44 Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels.A2358, A2359, A2360, A44 Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells.A2358, A2359, A2360, A44 Insulin is typically prescribed later in the course of T2D, after several oral medications such as DB00331, DB01120, or DB01261 have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.A2358, A2359, A2360, A44
Marketed as the brand name product Levemir, insulin detemir has a duration of action of 16-24 hours allowing for once-daily dosing, typically at bedtime.A2358, A2359, A2360, A44 Due to its duration of action, Levemir is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight.A2358, A2359, A2360, A44 Basal insulin is often combined with short-acting "bolus insulin" such as DB00046, DB01309, and DB01306 to provide higher doses of insulin required following meals.A2358, A2359, A2360, A44 Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.A2358, A2359, A2360, A44
Insulin detemir is produced using recombinant DNA technology in yeast cells.A2358, A2359, A2360, A44 This insulin analogue has a 14-C fatty acid, myristic acid, bound to the lysine amino acid at position B29. The myristoyl side chain increases self-association and albumin binding.A2358, A2359, A2360, A44 This along with slow systemic absorption from the injection site prolongs distribution of the hormone into tissues and results in a long duration of action. A2358, A2359, A2360, A44
Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst.A2358, A2359, A2360, A44 If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.A2358, A2359, A2360, A44
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Liraglutide | Liraglutide may increase the hypoglycemic activities of Insulin detemir. |
| Metreleptin | Metreleptin may increase the hypoglycemic activities of Insulin detemir. |
| Pegvisomant | The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin detemir. |
| Pioglitazone | The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin detemir. |
| Pramlintide | Pramlintide may increase the hypoglycemic activities of Insulin detemir. |
| Rosiglitazone | The risk or severity of congestive heart failure can be increased when Insulin detemir is combined with Rosiglitazone. |
| Lipoic acid | The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin detemir. |
| Edetic acid | Edetic acid may increase the hypoglycemic activities of Insulin detemir. |
| Esmolol | Esmolol may increase the hypoglycemic activities of Insulin detemir. |
| Landiolol | Landiolol may increase the hypoglycemic activities of Insulin detemir. |
| Gatifloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Gatifloxacin. |
| Moxifloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Moxifloxacin. |
| Enoxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Enoxacin. |
| Pefloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Pefloxacin. |
| Ciprofloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Ciprofloxacin. |
| Trovafloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Trovafloxacin. |
| Nalidixic acid | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Nalidixic acid. |
| Rosoxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Rosoxacin. |
| Cinoxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Cinoxacin. |
| Norfloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Norfloxacin. |
| Levofloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Levofloxacin. |
| Gemifloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Gemifloxacin. |
| Ofloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Ofloxacin. |
| Sparfloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Sparfloxacin. |
| Fleroxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Fleroxacin. |
| Technetium Tc-99m ciprofloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Technetium Tc-99m ciprofloxacin. |
| Garenoxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Garenoxacin. |
| Nemonoxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Nemonoxacin. |
| Flumequine | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Flumequine. |
| Enrofloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Enrofloxacin. |
| Orbifloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Orbifloxacin. |
| Sarafloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Sarafloxacin. |
| Difloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Difloxacin. |
| Pazufloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Pazufloxacin. |
| Prulifloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Prulifloxacin. |
| Delafloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Delafloxacin. |
| Sitafloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Sitafloxacin. |
| Oxolinic acid | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Oxolinic acid. |
| Rufloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Rufloxacin. |
| Pipemidic acid | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Pipemidic acid. |
| Grepafloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Grepafloxacin. |
| Lomefloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Lomefloxacin. |
| Temafloxacin | The therapeutic efficacy of Insulin detemir can be increased when used in combination with Temafloxacin. |
| Methyclothiazide | The risk or severity of hypoglycemia can be increased when Methyclothiazide is combined with Insulin detemir. |
| Chlorthalidone | The risk or severity of hypoglycemia can be increased when Chlorthalidone is combined with Insulin detemir. |
| Bendroflumethiazide | The risk or severity of hypoglycemia can be increased when Bendroflumethiazide is combined with Insulin detemir. |
| Metolazone | The risk or severity of hypoglycemia can be increased when Metolazone is combined with Insulin detemir. |
| Benzthiazide | The risk or severity of hypoglycemia can be increased when Benzthiazide is combined with Insulin detemir. |
| Hydroflumethiazide | The risk or severity of hypoglycemia can be increased when Hydroflumethiazide is combined with Insulin detemir. |
| Indapamide | The risk or severity of hypoglycemia can be increased when Indapamide is combined with Insulin detemir. |
| Chlorothiazide | The risk or severity of hypoglycemia can be increased when Chlorothiazide is combined with Insulin detemir. |
| Hydrochlorothiazide | The risk or severity of hypoglycemia can be increased when Hydrochlorothiazide is combined with Insulin detemir. |
| Trichlormethiazide | The risk or severity of hypoglycemia can be increased when Trichlormethiazide is combined with Insulin detemir. |
| Polythiazide | The risk or severity of hypoglycemia can be increased when Polythiazide is combined with Insulin detemir. |
| Quinethazone | The risk or severity of hypoglycemia can be increased when Quinethazone is combined with Insulin detemir. |
| Cyclopenthiazide | The risk or severity of hypoglycemia can be increased when Cyclopenthiazide is combined with Insulin detemir. |
| Epitizide | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Epitizide. |
| Protriptyline | Protriptyline may decrease the hypoglycemic activities of Insulin detemir. |
| Amoxapine | Amoxapine may decrease the hypoglycemic activities of Insulin detemir. |
| Trimipramine | Trimipramine may decrease the hypoglycemic activities of Insulin detemir. |
| Amineptine | Amineptine may decrease the hypoglycemic activities of Insulin detemir. |
| Dimetacrine | Dimetacrine may decrease the hypoglycemic activities of Insulin detemir. |
| Butriptyline | Butriptyline may decrease the hypoglycemic activities of Insulin detemir. |
| Dosulepin | Dosulepin may decrease the hypoglycemic activities of Insulin detemir. |
| Tianeptine | Tianeptine may decrease the hypoglycemic activities of Insulin detemir. |
| Oxaprotiline | Oxaprotiline may decrease the hypoglycemic activities of Insulin detemir. |
| Opipramol | Opipramol may decrease the hypoglycemic activities of Insulin detemir. |
| Amitriptylinoxide | Amitriptylinoxide may decrease the hypoglycemic activities of Insulin detemir. |
| Dibenzepin | Dibenzepin may decrease the hypoglycemic activities of Insulin detemir. |
| Quinupramine | Quinupramine may decrease the hypoglycemic activities of Insulin detemir. |
| Melitracen | Melitracen may decrease the hypoglycemic activities of Insulin detemir. |
| Lofepramine | Lofepramine may decrease the hypoglycemic activities of Insulin detemir. |
| Iprindole | Iprindole may decrease the hypoglycemic activities of Insulin detemir. |
| Imipramine oxide | Imipramine oxide may decrease the hypoglycemic activities of Insulin detemir. |
| Amitriptyline | Amitriptyline may decrease the hypoglycemic activities of Insulin detemir. |
| Imipramine | Imipramine may decrease the hypoglycemic activities of Insulin detemir. |
| Nortriptyline | Nortriptyline may decrease the hypoglycemic activities of Insulin detemir. |
| Doxepin | Doxepin may decrease the hypoglycemic activities of Insulin detemir. |
| Desipramine | Desipramine may decrease the hypoglycemic activities of Insulin detemir. |
| Clomipramine | Clomipramine may decrease the hypoglycemic activities of Insulin detemir. |
| Dapagliflozin | The risk or severity of hypoglycemia can be increased when Insulin detemir is combined with Dapagliflozin. |
| Canagliflozin | The risk or severity of hypoglycemia can be increased when Insulin detemir is combined with Canagliflozin. |
| Leuprolide | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Leuprolide. |
| Goserelin | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Goserelin. |
| Torasemide | The risk or severity of hypoglycemia can be increased when Torasemide is combined with Insulin detemir. |
| Nelfinavir | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Nelfinavir. |
| Indinavir | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Indinavir. |
| Ziprasidone | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Ziprasidone. |
| Etonogestrel | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Etonogestrel. |
| Desogestrel | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Desogestrel. |
| Olanzapine | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Olanzapine. |
| Megestrol acetate | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Megestrol acetate. |
| Clozapine | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Clozapine. |
| Levonorgestrel | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Levonorgestrel. |
| Progesterone | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Progesterone. |
| Chlorpromazine | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Chlorpromazine. |
| Haloperidol | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Haloperidol. |
| Ritonavir | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Ritonavir. |
| Piperazine | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Piperazine. |
| Medroxyprogesterone acetate | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Medroxyprogesterone acetate. |